| 摘要: |
| ［摘要］ 目的 探讨羟苯磺酸钙联合氯沙坦钾治疗糖尿病肾病（DN）蛋白尿临床疗效及安全性。方法 收集2011-03～2013-08收治的DN患者72例，根据抽签法将患者分为氯沙坦钾组和联合组，每组36例。氯沙坦钾组在常规治疗基础上用氯沙坦钾50 mg/d，口服。联合组在氯沙坦钾组基础上加羟苯磺酸钙胶囊口服500 mg/次，3次/d，治疗2个月。比较两组治疗前后血肌酐(Cr)、尿素氮(BUN)、24 h尿白蛋白排泄率(UAER)变化情况及治疗期间不良反应发生情况。结果 治疗前，两组Cr、BUN、24 h UAER无明显差异。治疗后，两组Cr、BUN与治疗前无明显差异(P>0.05)，24 h UAER均较治疗前明显降低(P<0.01)，联合组24 h UAER明显低于氯沙坦钾组(P<0.01)。两组均未出现明显的不良反应。结论 羟苯磺酸钙联合氯沙坦钾治疗DN能有效减少尿蛋白的排出量，降低UAER,保护肾功能，延缓DN的进展，值得临床借鉴。 |
| 关键词: 羟苯磺酸钙 氯沙坦钾 糖尿病肾病 蛋白尿 |
| DOI：10.3969/j.issn.1674-3806.2015.02.14 |
| 分类号:R 587.2 |
| 基金项目: |
|
| Clinical observation on effect of calcium dobesilate combined with losartan potassium on proteinuria in patients with diabetic nephropathy |
|
JIN Ming-wei
|
|
Department of Internal Medicine, the Seventh People′s Hospital of Zhengzhou, Henan 450016, China
|
| Abstract: |
| ［Abstract］ Objective To explore the effect of treating diabetic nephropathy(DN) by calcium dobesilate combined with losartan potassium on proteinuria in patients with DN, and its safety.Methods Seventy-two patients with DN who were treated were collected from Mar. 2011 to Aug. 2013.According to draw method，they were divided into losartan potassium group and combination group, 36 cases in each group. Losartan potassium group was orally treated with losartan potassium 50 mg/d on basis of conventional treatment.The combination group was orally treated with calcium dobesilate capsules,500 mg/time,3 times a day,on basis of losartan potassium group,the treatment course was two months.The change in serum creatinine(Cr), blood urea nitrogen(BUN), 24 hours′ urinary albuminexcretion rate(UAER) before and after treatment and the occurrence of adverse reactions during treatment were compared between the two groups.Results The Cr, BUN, 24 hours′ UAER before treatment had no significant difference between the two groups; after treatment,the Cr,BUN had no significant difference from those before treatment in the two groups(P>0.05), the 24 hours′ UAER was significantly lower than that before treatment in the two groups(P<0.01), and the 24 hours′ UAER in combination group were significantly lower than that in losartan potassium group(P<0.01). No obvious adverse reaction was found in the two groups.Conclusion Treating DN with losartan potassium combined with calcium dobesilate can reduce urinary protein excretion, decrease UAER, protect renal function, delay DN progress. It is worthy of clinical reference. |
| Key words: Calcium dobesilate Losartan potassium Diabetic nephropathy(DN) Proteinuria |
